Back to Homepage
Search
Advanced Search
EW WEEK No. 4
· FDA issues tentative approval to generic Xalatan
· Fera Pharmaceuticals now shipping erythromycin ophthalmic ointment
· FDA issues warning letter to researcher about promoting Ipsen’s Dysport
· Oxford BioMedica acquires intellectual property rights for gene-based ocular products
· Gov. Paterson proposes bill to require disclosure from PBM
· Gene expression may be linked to retinoblastoma progression
· Lead-based eye makeup may have fought infection in ancient Egypt

View this Issue

Get the Feed [Valid RSS]

Get the E-mail

Monthly Poll

Do you believe refractive volume will rebound during 2010?

Yes
No



View Poll Results
Resources

Ophthalmologists

Practice Managers

Patient Education

EyeSpaceMD

IOL Calculator
Click to Visit
 • Print Article

REPORTING LIVE FROM AAO
Intacs offers a potential alternative to corneal transplants for managing keratoconus
by Matt Young EyeWorld Staff Writer

Intacs, Food and Drug Administration-approved for correcting a small amount of myopia, is showing more and more promise for aiding keratoconus patients, said Yaron S. Rabinowitz, M.D., director of ophthalmology research, Cedars-Sinai Medical Hospital, Los Angeles, and one of the latest researchers on this topic.

Rabinowitz presented Intacs (Addition Technology Inc., Des Planes, Ill.) as an important alternative to the corneal transplant for keratoconus at The Cornea Society's Federated Scientific Session during the annual meeting of the American Academy of Ophthalmology, Anaheim, Calif.

Corneal transplants have historically helped manage the keratoconus condition, but Rabinowitz is convinced Intacs is a safer alternative in select patients.

Three patterns of Intacs
Source: Yaron Rabinowitz, M.D.
"Even though transplants are very successful, whenever you can avoid a transplant, there's an advantage to that," Rabinowitz said. "There's always a small chance with a transplant that you could lose the eye, whereas with Intacs that's highly unlikely."

Research results

In his retrospective study, Rabinowitz reviewed charts of all patients at Cedars-Sinai that had Intacs surgery for keratoconus with at least one year follow up. The patients were contact lens intolerant with a clear visual axis.

Of 12 eyes identified, nine experienced improved vision and are now contact lens tolerant. The patients also experienced a mean of three lines improved uncorrected acuity and a mean 2.4 lines in improved best-corrected acuity. Sphere was reduced a mean 3 D and astigmatism a mean 1.43 D.

"I think they were great results," Rabinowitz said. "Patients avoided a transplant and can see pretty well."

However, one patient had Intacs removed due to erosion of the segment and one had Intacs explanted from both eyes because of continuing visual changes one year postoperatively.

Regarding the eroded segment, Rabinowitz said, "That was really due to my inexperience - it was one of the first eyes I ever did - and I put the segments too superficially and it eroded, so I decided to remove the Intacs."

Rabinowitz is not the first to report on Intacs for keratoconus.

Joseph Colin, M.D., professor of ophthalmology, University of Bordeaux, France, and Dimitrios S. Siganos, M.D., Ph.D., who heads the Vlemma Eye Institute, Athens, Greece, also have done important work that showed the benefit of Intacs for keratoconus, Rabinowitz said. Colin's study results were published in Ophthalmology. Siganos' appeared in the American Journal of Ophthalmology.

Colin was the first to study this issue in Europe, where ophthalmologists are trying to avoid corneal transplants if possible because there is a shortage of corneal tissue, Rabinowitz said.

"What Dr. Colin showed was that when you put these rings in keratoconus, because the tissue in keratoconus is a lot more malleable and thinner, you actually get a much bigger effect and you can maybe correct up to 5 D or 6 D of myopia," Rabinowitz said. "When you fit them with contact lenses, not only were they more contact lens tolerant, they actually saw better with contacts than they saw before."

However, Rabinowitz said Colin's and Siganos' keratoconus patients were only mild to moderate, where in his study the patients had more severe keratoconus albeit with a clear visual axis, and he still got promising results - an important distinction.

Rabinowitz said he also performed his own study using only segments approved by the FDA, which was not the case with Colin's study.

Patients and patient expectations

Keratoconus patients with corneas less than 350 mm thick and those with central corneal scarring are not good candidates for Intacs, Rabinowitz said.

Even patients that expect to be independent of glasses or contact lenses following the procedure are poor candidates, he said.

While in many cases, Rabinowitz noted enhanced vision for Intacs patients in his study, "patients expectations should be limited to improved contact lens tolerance," he said. "With keratoconus patients, even though they have improved vision, they're still left with a certain amount of myopia and astigmatism - that never gets truly eliminated."

A new modification

Rabinowitz said his Intacs procedure includes placing a suction device on the eye; making channels in the cornea with two blades - first to the right, then to the left; and placing the plastic Intacs segments into the channels.

While the channels in the study participants were made with microkeratomes, Rabinowitz said he has recently used the IntraLase (IntraLase Corp., Irvine, Calif.) femtosecond laser to create them.

"IntraLase can create the channels a lot more elegantly than the blade, makes it a much simpler procedure and a lot less risky," Rabinowitz said. He said he is currently conducting research on using the IntraLase for this procedure.

In addition, a common side effect of blade usage is the creation of epithelial defects, which are virtually eliminated by the femtosecond laser, he said. The laser is also much more accurate than the blade in creating channel depth, he said.

Editors' note: Rabinowitz has no financial interests in Addition Technology or IntraLase.


Contact Information
Rabinowitz:
310-423-9640, 310-423-9649, rabinowitzy@cshs.org
mailto:cioffi2@aol.com


Expectations should be limited to improved CL
tolerance.






ASCRS
Copyright © 1997-2010 EyeWorld News Service
This site is optimized for 1024 X 768 Resolution


Visit EyeWorld.mobi for a PDA optimized experience